



ISTITUTO ITALIANO
DI TECNOLOGIA

TITLE

2,6-disubstituted 4-amino-pyrimidines and 4-amino-triazines as treatments for processes driven by RhoJ/Cdc42 signaling, including melanoma, other cancers, retinal disorders, and cardiomyopathies.

INVENTORS

Marco DE VIVO, Anand GANESAN, Jose Antonio ORTEGA MARTINEZ, Sohail JAHID

DESCRIPTION

The present disclosure relates to novel 2-heterocycloalkyl-6-aryl-4-aminopyrimidine and 2-heterocycloalkyl-6-aryl-4-aminotriazine derivatives, collectively termed 2,6-disubstituted-4-amino-pyrimidines and 2,6-disubstituted-4-amino-triazines. The invention also relates to the use of said compounds, alone or in combination with other current anticancer drugs, in the treatment melanoma and/or growth of tumors in mammals. In particular, the here disclosed 2,6-disubstituted-4-amino-pyrimidines are potent inhibitors of RhoJ, and other members of the Cdc42 family, interaction with Pak1

APPLICATIONS

Drug-resistant cancers treatment, melanoma treatment, retinal disorders treatment, cardiomyopathies treatment

KEYWORDS

Anticancer drugs, Rho-J inhibition, 4-amino pyrimidine scaffold, 4-amino triazine scaffold

BIBLIOGRAPHIC DATA

Composti e composizioni per il trattamento di cancro, disordini della retina e cardiomiopatie

Application Number	IT102017000047189
Priority Date	May 02, 2017
Applicants	Fondazione Istituto Italiano di Tecnologia, The Regents of the University of California

CONTACTS

Technology Transfer Office	Angela Gagliolo	+39 010 71781 986
		angela.gagliolo@iit.it